MeSH D006457 - paroxysmal hemoglobinuria
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals | Eculizumab | Soliris | 2007-03-16 | $4,068.9 M | Q2/20-Q1/21 | |
| Ravulizumab | Ultomiris | 2019-07-02 | $1,200.8 M | Q2/20-Q1/21 | ||
| Amgen | Eculizumab | Bekemv | 2023-04-19 | |||
| Orphan Medical | Pegcetacoplan | Aspaveli | 2021-12-13 |
Clinical Trials
Historical Success Rate
Phase 1
40%2/5
Phase 2
23%9/39
Phase 3
64%9/14
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use